Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography†

Ryota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, +11

Hepatology

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng, +202

The Lancet

Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma +6

Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma

Vinod Kumar, Naoya Kato, Yuji Urabe, +12

Nature Genetics

Genome-wide Association StudyHepatologyHepatitis CViral HepatitisImmunology +10

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle, +200

The Lancet Oncology

OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib +8

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, +34

Annals of Oncology

S-1 Versus GemcitabineGastrointestinal OncologyMedicineBiliary CancerPathology +5

A Novel Sequence Found at the 3′-Terminus of Hepatitis C Virus Genome

Toshitake Tanaka, Naoya Kato, M.J. Cho, +1

Biochemical and Biophysical Research Communications

Virus StructureMolecular VirologyHepatitis CViral HepatitisGenetics +8

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Naoya Kato, Yasushi Shiratori, Jun Kato, +4

Journal of Clinical Investigation

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan

Yasushi Shiratori, Shuichiro Shiina, Masatoshi Imamura, +11

Hepatology

ImmunologyHepatitis BPathologyAutoimmune Liver DiseaseHcc Patients +20

Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver disease

Naoya Kato, Osamu Yokosuka, Kazuhiko Hosoda, +3

Hepatology

Viral ReplicationHepatitis C VirusPathologyCirrhosisHepatic Disorders +14

Major virulence factors, VacA and CagA, are commonly positive in <i>Helicobacter pylori</i> isolates in Japan

Shingo Maeda, K. Ogura, Hisako Yoshida, +5

Gut